Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Baxter
McKinsey
Express Scripts
Cantor Fitzgerald
Covington

Generated: July 19, 2019

DrugPatentWatch Database Preview

Patent: 9,241,931

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,241,931
Title:Compound useful for the treatment of degenerative and inflammatory diseases
Abstract: A pyrazolopyridine compound according to Formula I, able to inhibit JAK is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant JAK activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6. ##STR00001##
Inventor(s): Menet; Christel Jeanne Marie (Mechelen, BE), Hodges; Alastair James (Essex, GB), Vater; Huw David (Essex, GB)
Assignee: GALAPAGOS NV (Mechelen, BE)
Application Number:14/457,071
Patent Claims:see list of patent claims

Details for Patent 9,241,931

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Bristol Myers Squibb ORENCIA abatacept INJECTABLE; IV (INFUSION) 125118 001 2005-12-23 ➤ Sign Up GALAPAGOS NV (Mechelen, BE) ➤ Sign Up RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up GALAPAGOS NV (Mechelen, BE) ➤ Sign Up RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up GALAPAGOS NV (Mechelen, BE) ➤ Sign Up RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up GALAPAGOS NV (Mechelen, BE) ➤ Sign Up RX Orphan search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up GALAPAGOS NV (Mechelen, BE) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 9,241,931

Country Patent Number Publication Date
South Africa 201307793 Apr 29, 2015
World Intellectual Property Organization (WIPO) 2012146657 Nov 01, 2012
World Intellectual Property Organization (WIPO) 2012146659 Nov 01, 2012
Uruguay 34037 Nov 30, 2012
United States of America 2012277247 Nov 01, 2012
United States of America 2014051677 Feb 20, 2014
United States of America 2015031706 Jan 29, 2015
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Fuji
Moodys
Queensland Health
QuintilesIMS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.